Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial

AIMS: A randomized, double-blind, placebo-controlled study was conducted to investigate the safety and efficacy of mipomersen, an apolipoprotein B-100 (apoB) synthesis inhibitor, in patients who are statin intolerant and at high risk for cardiovascular disease (CVD). METHODS AND RESULTS: Thirty-thre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Visser, Maartje E., Wagener, Gilbert, Baker, Brenda F., Geary, Richard S., Donovan, Joanne M., Beuers, Ulrich H.W., Nederveen, Aart J., Verheij, Joanne, Trip, Mieke D., Basart, Dick C.G., Kastelein, John J.P., Stroes, Erik S.G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2012
Konular:
Clinical Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3751967/
https://ncbi.nlm.nih.gov/pubmed/22507979
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehs023
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller